Last reviewed · How we verify
MEDI-534
At a glance
| Generic name | MEDI-534 |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants (PHASE1, PHASE2)
- Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (PHASE1)
- Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children (PHASE1)
- Study to Evaluate MEDI-534 in Healthy Adults
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI-534 CI brief — competitive landscape report
- MEDI-534 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI